You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)在2019年ASCO大會公佈CS1001-101臨床試驗數據
阿思達克 06-03 07:52

基石藥業(02616.HK)公布,在2019年美國臨床腫瘤學會(ASCO)年會上,以海報形式公布CS1001-101的臨床試驗更新數據。

CS1001-101是一項針對晚期實體瘤或淋巴瘤患者展開的1a/1b期、開放性、多劑量給藥的劑量探索和擴展研究。試驗數據顯示,CS1001耐受性良好,具有預期的藥代動力學特徵,在各種類型的腫瘤中都能觀察到持久的抗腫瘤活性。數據顯示CS1001對多種實體瘤和淋巴瘤有效。

公司董事長、執行董事兼首席執行官江寧軍博士表示,CS1001也是基石藥業三款腫瘤免疫骨幹(backbone)產品之一。公司已為這一候選藥物制定系統的臨床開發計劃,用於評估它單藥及聯合療法在治療肺癌、胃癌和其他晚期腫瘤上的潛力。

公司首席醫學官楊建新博士表示,非常高興地公佈CS1001的最新數據來進一步驗證它的安全性和有效性。這些數據也將支持CS1001在註冊性試驗中的持續開發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account